I am keen on searching for new and progressive ophthalmic technologies and am known to be an early adopter of many innovations, including trifocal IOLs and laser-assisted cataract surgery. Because adding the FineVision trifocal IOL (PhysIOL) to our armamentarium revolutionized our refractive practice, I have been sure to keep a close eye on other new trifocal IOL designs.
• The RevIOL Tri-ED is a plate-haptic hydrophilic acrylic IOL
with a trifocal diffractive structure on its anterior surface.
• The IOL provides a near add of 3.00 D and an intermediate add of 1.50 D.
I have had positive experiences with VSY's other products, and, therefore, when the company announced its entrance into the trifocal IOL market with the RevIOL Tri-ED (Figure 1), I was happy to give it a try. It is a plate-haptic hydrophilic acrylic IOL with a hydrophobic surface and a trifocal diffractive structure on its anterior surface. The combination of an active-diffractive optic structure with proprietary curvature and slightly negative asphericity results in extended depth of focus for presbyopic patients (Figure 2). According to the company, the diffractive zone design creates higher modular transfer function values between the near to intermediate and intermediate to distance focusing areas compared with monofocal, bifocal, and other trifocal IOLs and clearer vision at all distances.1 The active-diffractive optic also protects the retina by blocking pale blue light.
Figure 1. Features of the RevIOL Tri-ED.
Figure 2. The RevIOL Tri-ED's active-diffractive optic results in extended depth of focus.
Because we do not yet have a true accommodating IOL, I like VSY's idea of developing the trifocal concept further. The selected disparity between near and intermediate focus (3.00 D of add for near and 1.50 D for intermediate) seems to work effectively to create sharp vision at all distances.
We are currently assessing the defocus curve and clinical results with the RevIOL Tri-ED. Initial results with this lens seem promising, and my patients have been enjoying spectacle independence in their usual daily activities. I expect more new trifocal IOLs will enter the market soon.
1. Data on file with VSY.
Pavel Stodulka, MD, PhD
- Chief Eye Surgeon, CEO of Gemini Eye Clinics, Czech Republic
- Financial disclosure: None